Abstract：
To determine 1-year and 5-year total healthcare costs and healthcare resource (HRU) associated with renal cell carcinoma (RCC) in older Americans, from a healthcare sector perspective.
This was a longitudinal, retrospective cohort study using the Surveillance, Epidemiology and End Results-Medicare linked data (2006-2014), which included older (≥66 years) patients with primary RCC and 1:5 matched noncancer controls. Patients/controls were followed from diagnosis (pseudo-diagnosis for controls) until death or up to loss-to-follow-up (censored). Per-patient average 1-year and 5-year cumulative total and incremental total healthcare costs and HRU were reported.
A total of 11,228 RCC patients were matched to 56,140 controls. Per-patient cumulative average 1-year (incremental = $38,291 [$36,417-$40,165]; $57,588 vs. $19,297) and 5-year (incremental = $68,004 [$55,123-$80,885]; $183,550 vs. $115,547) total costs (excluding prescription drug costs) were 3 and 1.6 times higher for RCC vs. controls. These estimates were 3.6 and 1.7 times higher for RCC vs. controls when prescription costs were included in total costs. Prescription drug costs accounted for 8.4% (incremental = $3,715) and 18.1% (incremental = $15,375) of the 1-year and 5-year incremental total costs, respectively. RCC patients had greater cumulative number of hospitalizations, emergency department visits and prescriptions in 1- and 5-years, compared to controls.
Average first year total cost for a patient with incident diagnosis of RCC is substantially higher than that for controls and it varies depending on the stage at diagnosis. Study findings could help in planning future resource allocation and in determining research and unmet needs in this patient population.
This was a longitudinal, retrospective cohort study using the Surveillance, Epidemiology and End Results-Medicare linked data (2006-2014), which included older (≥66 years) patients with primary RCC and 1:5 matched noncancer controls. Patients/controls were followed from diagnosis (pseudo-diagnosis for controls) until death or up to loss-to-follow-up (censored). Per-patient average 1-year and 5-year cumulative total and incremental total healthcare costs and HRU were reported.
A total of 11,228 RCC patients were matched to 56,140 controls. Per-patient cumulative average 1-year (incremental = $38,291 [$36,417-$40,165]; $57,588 vs. $19,297) and 5-year (incremental = $68,004 [$55,123-$80,885]; $183,550 vs. $115,547) total costs (excluding prescription drug costs) were 3 and 1.6 times higher for RCC vs. controls. These estimates were 3.6 and 1.7 times higher for RCC vs. controls when prescription costs were included in total costs. Prescription drug costs accounted for 8.4% (incremental = $3,715) and 18.1% (incremental = $15,375) of the 1-year and 5-year incremental total costs, respectively. RCC patients had greater cumulative number of hospitalizations, emergency department visits and prescriptions in 1- and 5-years, compared to controls.
Average first year total cost for a patient with incident diagnosis of RCC is substantially higher than that for controls and it varies depending on the stage at diagnosis. Study findings could help in planning future resource allocation and in determining research and unmet needs in this patient population.
摘要：
为了确定与美国老年人肾细胞癌（RCC）相关的1年和5年总医疗保健费用和医疗保健资源（HRU），从医疗保健行业的角度来看。
这是纵向的,使用监测的回顾性队列研究，流行病学和最终结果与医疗保险相关数据(2006-2014年)，其中包括年龄较大(≥66岁)的原发性RCC患者和1:5匹配的非癌症对照。患者/对照从诊断(对照的伪诊断)到死亡或直至失访(审查)。报告了每位患者平均1年和5年累计总医疗费用和增量总医疗费用以及HRU。
共有11,228名RCC患者与56,140名对照进行匹配。每患者1年累计平均(增量=38,291美元[36,417-40,165美元]；57,588美元vs.19,297美元)和5年期(增量=68,004美元[55,123-80,885美元]；183,550美元与$115,547）的总费用（不包括处方药费用）是RCC的3倍和1.6倍。controls.RCC的这些估计值分别为3.6和1.7倍。当处方成本包括在总成本中时进行控制。处方药费用占1年和5年总费用增量的8.4%（增量=3,715元）和18.1%（增量=15,375元），分别。RCC患者的累计住院次数较多，1年和5年的急诊科就诊和处方，与对照组相比。
发生RCC的患者的平均第一年总费用大大高于对照组，并且因诊断阶段而异。研究结果可以帮助规划未来的资源分配以及确定该患者人群的研究和未满足的需求。
这是纵向的,使用监测的回顾性队列研究，流行病学和最终结果与医疗保险相关数据(2006-2014年)，其中包括年龄较大(≥66岁)的原发性RCC患者和1:5匹配的非癌症对照。患者/对照从诊断(对照的伪诊断)到死亡或直至失访(审查)。报告了每位患者平均1年和5年累计总医疗费用和增量总医疗费用以及HRU。
共有11,228名RCC患者与56,140名对照进行匹配。每患者1年累计平均(增量=38,291美元[36,417-40,165美元]；57,588美元vs.19,297美元)和5年期(增量=68,004美元[55,123-80,885美元]；183,550美元与$115,547）的总费用（不包括处方药费用）是RCC的3倍和1.6倍。controls.RCC的这些估计值分别为3.6和1.7倍。当处方成本包括在总成本中时进行控制。处方药费用占1年和5年总费用增量的8.4%（增量=3,715元）和18.1%（增量=15,375元），分别。RCC患者的累计住院次数较多，1年和5年的急诊科就诊和处方，与对照组相比。
发生RCC的患者的平均第一年总费用大大高于对照组，并且因诊断阶段而异。研究结果可以帮助规划未来的资源分配以及确定该患者人群的研究和未满足的需求。
